PYC to commence first in human studies for retinal disease

May 10, 2022 02:14 PM AEST | By Aditi Sarkar
Follow us on Google News:


  • PYC Therapeutics has completed its pharmacokinetic (PK) studies in Non-Human Primates (NHPs) successfully.
  • Results from PK studies will aid the progression of PYC’s investigational drug candidate for evaluation in human beings
  • The results also confirm the efficiency of PYC’s next-generation RNA technology for curing retinal disease
  • PYC will start ‘first in human’ studies after a successful IND

Biotechnology company PYC Therapeutics (ASX: PYC) has shared an upbeat update on results from Pharmacokinetic studies (PK) for treating blinding eye disease called Retinitis Pigmentosa type 11 (RP11).

The pre-clinical stage biotechnology firm has received encouraging results from PK studies in non-human primates for its investigational drug candidate. The key results support the advancement of its investigational drug candidate into ‘first in human’ assessment for RP11. It also confirms the efficiency of the company’s next-generation RNA technology for curing retinal disease.

PYC combines RNA-based drug design and proprietary drug delivery technology to create a new generation of RNA therapeutics for genetic diseases. The company is employing its proprietary library of naturally derived cell-penetrating peptides to overcome the major difficulties of current genetic medicines.

Demonstrated important drug-like properties

This is the first program in PYC’s pipeline of next-generation RNA therapies, which is advancing towards clinical development. Currently, there are no approved therapies for RP11 and no undergoing clinical trials for investigational units.

Related read: From VIP to VRT: Top five dividend-paying stocks from ASX healthcare

Three important findings of PK study

Image source: © 2022 Kalkine Media®

Transition into a clinical-stage company

PYC is well positioned to file an Investigational New Drug (IND) application for its drug candidate in RP11 with the US Food and Drug Administration in the second half of this year. The company has already commenced Good Laboratory Practice toxicology studies required to support this IND.

PYC will start ‘first in human’ studies after a successful IND. This will mark the transition of PYC into a clinical-stage Company with the first product borne out of its next-generation platform for the creation of novel RNA therapeutics.

Stock information: Shares of PYC were trading at AU$0.084, as spotted at 10:52 AM AEST on 10 May 2022.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK